WFH/LinkedIn
Feb 28, 2026, 14:48
WFH Acknowledges BioMarin’s Decision to Discontinue ROCTAVIAN
World Federation of Hemophilia (WFH) shared a post on LinkedIn:
“WFH Statement: the WFH acknowledges BioMarin’s decision to discontinue ROCTAVIAN and the importance of this development for the hemophilia community.
We urge BioMarin and other gene therapy developers to continue rigorous long-term safety monitoring of all discontinued products, and to preserve and share relevant clinical data that can inform ongoing scientific understanding and support patient safety.
For the full WFH position and our emphasis on preserving data in the WFH Gene Therapy Registry, please read our complete statement here.”
Other articles about World Federation of Hemophilia on Hemostasis Today.
-
Jun 1, 2026, 13:44Milad Abdalla: Elevating Phlebotomy Standards – Why Order of Draw and Blood Cultures Matter
-
Jun 1, 2026, 13:39Abdul Mannan: The Moral Injury of Practising Haemato-Oncology in a Resource-Limited Setting
-
Jun 1, 2026, 13:34Filza Aslam: What Does a Patient Journey Partner Actually Do in Bleeding Disorders?
-
Jun 1, 2026, 13:33Darine Ghanem: Advancing Health Equity in Care at the LATAM Meeting
-
Jun 1, 2026, 13:23Skye Collado: Miller-Keystone Blood Center Expands Community Impact Through the Addition of New Bloodmobiles
-
Jun 1, 2026, 12:37Rutuja Mahadik: Anemia is More Than Just Feeling Tired
-
Jun 1, 2026, 12:36Ankur Jindal: Large-Vessel Inflammation and Immune Dysregulation in Wiskott–Aldrich Syndrome
-
Jun 1, 2026, 12:35Shadi Almassri: Conditions That Can Cause False High or False Low HbA1c Results
-
Jun 1, 2026, 12:22Ed Davidson: Clot Removing Technology That Can Change the Game